What you say makes sense. But the EU is facing the advent of ISO 15197:2015 as of the end of September. Most diabetic products currently on the EU market will become by fiat, non-conforming ... because of, you guessed it, hematocrit issues. So in my mind the prospective acquirer might be a company from the EU or a company that sells to the EU, or a foreign company looking for a cheap foothold in the U.S. market. A strategic would be someone in the U.S. or a trans-national already in the in-vitro business. I think that slightly less likely.